EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Biomarkers of mRNA vaccine efficacy derived from mechanistic modeling of tumor-immune interactions

Chrysovalantis Voutouri iD, Lance L Munn, Triantafyllos Stylianopoulos, Rakesh K Jain iD

PLOS Computational Biology · 12.06.2025 · 21 (6) · e1013163

DOI: 10.1371/journal.pcbi.1013163 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Computational Biology, online erschienen am 12.06.2025. Verfasst von Chrysovalantis Voutouri und 3 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Biophysics Laboratory, Department of Mechanical and Manufacturing Engineering, University of Cyprus, Nicosia, Cyprus. Hauptthemen laut MEDLINE: Neoplasms, Cancer Vaccines, mRNA Vaccines, Biomarkers, Tumor. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, NCI NIH HHS, NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The success of mRNA vaccines against infectious diseases such as COVID-19 has opened new avenues for their application in oncology. In cancer immunotherapy, mRNA vaccines—typically encapsulated in lipid nanoparticles (LNPs) 100–200 nm in size—enable delivery of tumor-specific antigens to activate immune responses. Here, we investigated the efficacy of mRNA vaccines in cancer by modeling tumor-immune interactions and tumor microenvironment (TME) dynamics to identify predictive biomarkers. Using a mechanistic mathematical model, we simulated tumor growth, immune cell dynamics, and vaccine pharmacokinetics in virtual cohorts of 1,635 patients generated via Latin hypercube sampling. Our simulations demonstrated a 45% average tumor size reduction and a 60% increase in CD8 + T cell infiltration in responsive tumors. Multiple regression analyses validated the predictive power of both pre- and on-treatment biomarkers. Key predictors of vaccine efficacy included antigen-presenting cell (APC) density and cytotoxic T cell fraction. Specifically, an APC density above 500 cells/mm³ in lymph nodes correlated with a 55% increase in vaccine response rates, while a cytotoxic T cell fraction above 20% in tumors was associated with a 60% reduction in tumor volume. A reduced M2/M1 macrophage ratio further improved treatment outcomes by 50%, highlighting the role of reprograming immunosuppressive macrophages. TME characteristics significantly influenced vaccine efficacy. Low extracellular matrix (ECM) density—modeled as a 5–10 × increase in hydraulic conductivity—combined with medium cytokine levels (IL-2 and TNF-α at 10–50 pg/ml), created optimal conditions for immune activation. Under these conditions, vaccine uptake improved by 35% and cytotoxic T cell infiltration increased by 65%, resulting in up to a 50% improvement in therapeutic outcomes. Model predictions aligned with pre-clinical data from melanoma and breast cancer models. These findings provide a framework for optimizing mRNA vaccine strategies and advancing personalized cancer immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsCancer VaccinesmRNA VaccinesBiomarkers, TumorHumansTumor MicroenvironmentCOVID-19Computational BiologyImmunotherapyComputer SimulationModels, ImmunologicalT-Lymphocytes, CytotoxicRNA, Messenger

Substanzen

Cancer VaccinesmRNA VaccinesBiomarkers, TumorRNA, Messenger

Autor:innen und Institutionen

  • Cancer Biophysics Laboratory, Department of Mechanical and Manufacturing Engineering, University of Cyprus, Nicosia, Cyprus.
  • Edwin L Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States of America.

ORCID-Profile: Chrysovalantis Voutouri, Rakesh K Jain

Förderung

  • NINDS NIH HHS
  • NCI NIH HHS
  • NIH
  • National Foundation for Cancer Research, Jane’s Trust Foundation, Niles Albright Research Foundation, and the Harvard Ludwig Cancer Center
  • European Research Council
  • Research and Innovation Foundation of Cyprus

Zitieren

APA

Voutouri, C., Munn, L. L., Stylianopoulos, T., & Jain, R. K. (2025). Biomarkers of mRNA vaccine efficacy derived from mechanistic modeling of tumor-immune interactions. PLOS Computational Biology, 21(6), e1013163. https://doi.org/10.1371/journal.pcbi.1013163

Vancouver

Voutouri C, Munn LL, Stylianopoulos T, Jain RK. Biomarkers of mRNA vaccine efficacy derived from mechanistic modeling of tumor-immune interactions. PLOS Computational Biology. 2025;21(6):e1013163. doi:10.1371/journal.pcbi.1013163

BibTeX
@article{Voutouri2025,
  author = {Voutouri, Chrysovalantis and Munn, Lance L and Stylianopoulos, Triantafyllos and Jain, Rakesh K},
  title = {Biomarkers of mRNA vaccine efficacy derived from mechanistic modeling of tumor-immune interactions},
  journal = {PLOS Computational Biology},
  year = {2025},
  volume = {21},
  number = {6},
  pages = {e1013163},
  doi = {10.1371/journal.pcbi.1013163}
}
Kostenlos starten →